Weekly Taxol (Paclitaxel): What It Involves
After EC, the next phase is weekly Taxol (paclitaxel), alongside HER2-targeted therapy (Phesgo). This page explains what a typical weekly Taxol appointment involves and what it’s trying to do before surgery.
Weekly Taxol (Paclitaxel): What It Involves
This is the “how it works” page for the second stage of chemotherapy: weekly Taxol.
Taxol is a different kind of chemotherapy to EC. Instead of damaging DNA directly, it interferes with how cells divide — which makes it particularly effective against fast-growing cancer cells.
What is Taxol?
Taxol is the brand name for paclitaxel, a taxane chemotherapy drug.
In simple terms: it disrupts the “scaffolding” cells need to split into two, which can slow or stop cancer growth.
Why weekly?
Weekly dosing is common because it can:
- keep a steady treatment intensity
- sometimes be better tolerated than higher-dose schedules
- allow clinicians to adjust quickly if side effects build up
What a weekly Taxol appointment typically involves
A typical week can look like this:
- Blood test(s) to make sure it’s safe to treat
- Quick review of symptoms (especially numbness/tingling in hands/feet)
- Pre-meds (often steroids + antihistamines) to reduce infusion reactions
- Taxol infusion with monitoring
- Home plan: manage aches, bowel changes, sleep disruption, skin/nail care, and when to call the team
What side effects people often talk about (in plain English)
Everyone’s experience is unique, but common themes with weekly Taxol include:
- Fatigue (it can accumulate over weeks)
- Aches and pains (muscle/joint “flu-ish” feelings)
- Skin and nail changes
- Neuropathy risk (tingling, numbness, or burning in fingers/toes)
The big one that clinicians track closely is neuropathy, because it can affect day-to-day function and sometimes needs dose changes.
How this fits with HER2-positive treatment
For HER2-positive breast cancer, chemo is often paired with HER2-targeted therapy (for me: Phesgo).
Chemo attacks fast-dividing cells in general; HER2 treatment targets a specific “growth signal” that HER2-positive cancer cells rely on. Together, they aim to maximise the chance of a complete response before surgery.